Investors & Media

Investors & Media

Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics®, which are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity.

Please use the Investor & Media drop down menu to access more tools and information

Merus - Closing In On Cancer
Upcoming Events
More events are coming soon.

Summary Share Price

Copyright West LLC. Minimum 15 minutes delayed.